ERBB2 and breast carcinoma: Interestingly, HER2-positive breast cancer patients with higher intratumor HER2 mRNA levels had lower risk of death when treated with T-DM1 than when with capecitabine plus lapatinib (HR, 0.53; 95% CI, 0.37–0.76).